Compare
Neuraxis, Inc vs Nuwellis, Inc. vs Escalon Medical Corp vs CapsoVision, Inc
| Latest fiscal year | Neuraxis, Inc NRXS | Nuwellis, Inc. NUWE | Escalon Medical Corp ESMC | CapsoVision, Inc CV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $3.57M | $8.27M | $12.74M | $13.55M |
| Revenue growth (YoY) | +32.9% | -5.4% | +5.7% | +15.3% |
| Gross margin | 84.2% | 62.0% | 43.7% (computed) | 52.9% |
| Operating margin | -219.4% | -134.3% | 0.4% | -188.3% |
| Net margin | -218.5% | -211.9% | 31.5% | -186.8% |
| Net income | -$7.80M | -$17.52M | $4.01M | -$25.32M |
| EPS (Diluted) | -$0.95 | -$25.39 | $0.27 | -$1.03 |
| Operating cash flow | -$6.43M | -$10.81M | -$402.6K | -$22.86M |
| Free cash flow | -$6.46M | -$10.90M | -$407.0K | -$22.95M |
| Cash & equivalents | $4.97M | $1.08M | $3.07M | n/a |
| Total assets | $6.40M | $6.12M | $9.13M | $18.16M |
| Total liabilities | $3.00M | $3.49M | $3.20M | $4.90M |
| Shareholders' equity | $3.40M | $2.62M | $5.93M | $13.26M |
| Return on year-end equity | -229.5% | -667.7% | 67.7% | -190.9% |
| Shares outstanding | 10.65M | 1.69M | 7.42M | 46.87M |
Revenue, most recent five fiscal years
| Fiscal year | Neuraxis, Inc | Nuwellis, Inc. | Escalon Medical Corp | CapsoVision, Inc |
|---|---|---|---|---|
| Latest | $3.57M Ended 2025-12-31 | $8.27M Ended 2025-12-31 | $12.74M Ended 2026-06-30 | $13.55M Ended 2025-12-31 |
| 1 year earlier | $2.69M Ended 2024-12-31 | $8.74M Ended 2024-12-31 | $12.05M Ended 2025-06-30 | $11.76M Ended 2024-12-31 |
| 2 years earlier | $2.46M Ended 2023-12-31 | $8.86M Ended 2023-12-31 | $11.98M Ended 2024-06-30 | n/a |
| 3 years earlier | $2.68M Ended 2022-12-31 | $8.54M Ended 2022-12-31 | $12.18M Ended 2023-06-30 | n/a |
| 4 years earlier | n/a | $7.92M Ended 2021-12-31 | $10.70M Ended 2022-06-30 | n/a |